{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:28:32Z","timestamp":1793035712960,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00467-021-05406-z","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T22:03:01Z","timestamp":1641420181000},"page":"1945-1955","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Is autosomal dominant polycystic kidney disease an early sweet disease?"],"prefix":"10.1007","volume":"37","author":[{"given":"Ang\u00e9lique","family":"Dachy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Decuypere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Vennekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Jouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-6088","authenticated-orcid":false,"given":"Djalila","family":"Mekahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"5406_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/gft521","volume":"29","author":"I Rowe","year":"2014","unstructured":"Rowe I, Boletta A (2014) Defective metabolism in polycystic kidney disease: potential for therapy and open questions. Nephrol Dial Transplant 29:1480\u20131486. https:\/\/doi.org\/10.1093\/ndt\/gft521","journal-title":"Nephrol Dial Transplant"},{"key":"5406_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V, Ulisse V et al (2013) Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med 19:488\u2013493. https:\/\/doi.org\/10.1038\/nm.3092","journal-title":"Nat Med"},{"key":"5406_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak KL, Hopp K (2020) Metabolic reprogramming in autosomal dominant polycystic kidney disease evidence and therapeutic potential. Clin J Am Soc Nephrol 15:577\u2013584. https:\/\/doi.org\/10.2215\/CJN.13291019","journal-title":"Clin J Am Soc Nephrol"},{"key":"5406_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s42003-018-0200-x","volume":"1","author":"C Podrini","year":"2018","unstructured":"Podrini C, Rowe I, Pagliarini R, Costa ASH et al (2018) Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun Biol 1:194. https:\/\/doi.org\/10.1038\/s42003-018-0200-x","journal-title":"Commun Biol"},{"key":"5406_CR5","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","volume":"310","author":"KR Kipp","year":"2016","unstructured":"Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Physiol 310:F726\u2013F731. https:\/\/doi.org\/10.1152\/ajprenal.00551.2015","journal-title":"Am J Physiol Physiol"},{"key":"5406_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","volume":"27","author":"G Warner","year":"2016","unstructured":"Warner G, Hein KZ, Nin V, Edwards M et al (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27:1437\u20131447. https:\/\/doi.org\/10.1681\/ASN.2015020132","journal-title":"J Am Soc Nephrol"},{"key":"5406_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","volume":"30","author":"JA Torres","year":"2019","unstructured":"Torres JA, Kruger SL, Broderick C, Amarlkhagva T et al (2019) Ketosis ameliorates renal cyst growth in polycystic kidney disease. Cell Metab 30:1007\u20131023. https:\/\/doi.org\/10.1016\/j.cmet.2019.09.012","journal-title":"Cell Metab"},{"key":"5406_CR8","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD Jr et al (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462\u20132467. https:\/\/doi.org\/10.1073\/pnas.1011498108","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5406_CR9","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","volume":"7","author":"MY Chang","year":"2017","unstructured":"Chang MY, Ma TL, Hung CC, Tian YC et al (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep 7:7161. https:\/\/doi.org\/10.1038\/s41598-017-07300-x","journal-title":"Sci Rep"},{"key":"5406_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","volume":"100","author":"RD Perrone","year":"2021","unstructured":"Perrone RD, Abebe KZ, Watnick T, Althouse AD et al (2021) Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int 100:684\u2013696. https:\/\/doi.org\/10.1016\/j.kint.2021.06.013","journal-title":"Kidney Int"},{"key":"5406_CR11","doi-asserted-by":"publisher","unstructured":"Brosnahan GM, Wang W, Gitomer B, Struemph T et al (2021) Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study. Am J Kidney Dis 12:S0272-6386(21)00790-3.\u00a0https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.026","DOI":"10.1053\/j.ajkd.2021.06.026"},{"key":"5406_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.199","volume":"84","author":"X Wang","year":"2013","unstructured":"Wang X, Zhang S, Liu Y, Spichtig D et al (2013) Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. Kidney Int 84:962\u2013968. https:\/\/doi.org\/10.1038\/ki.2013.199","journal-title":"Kidney Int"},{"key":"5406_CR13","doi-asserted-by":"publisher","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","volume":"10","author":"S Kapoor","year":"2015","unstructured":"Kapoor S, Rodriguez D, Riwanto M, Edenhofer I et al (2015) Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS ONE 10:e0125603. https:\/\/doi.org\/10.1371\/journal.pone.0125603","journal-title":"PLoS ONE"},{"key":"5406_CR14","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1159\/000368540","volume":"40","author":"D Rodriguez","year":"2015","unstructured":"Rodriguez D, Kapoor S, Edenhofer I, Segerer S et al (2015) Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease. Kidney Blood Press Res 40:638\u2013647. https:\/\/doi.org\/10.1159\/000368540","journal-title":"Kidney Blood Press Res"},{"key":"5406_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","volume":"47","author":"WN Leonhard","year":"2019","unstructured":"Leonhard WN, Song X, Kanhai AA, Iliuta IA et al (2019) Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine 47:436\u2013445. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.041","journal-title":"EBioMedicine"},{"key":"5406_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1159\/000503423","volume":"44","author":"M Fliszkiewicz","year":"2019","unstructured":"Fliszkiewicz M, Niemczyk M, Kulesza A, \u0141abu\u015b A, P\u0105czek L (2019) Glucose and lipid metabolism abnormalities among patients with autosomal dominant polycystic kidney disease. Kidney Blood Press Res 44:1416\u20131422. https:\/\/doi.org\/10.1159\/000503423","journal-title":"Kidney Blood Press Res"},{"key":"5406_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/00365513.2010.527012","volume":"70","author":"M Pietrzak-Nowacka","year":"2010","unstructured":"Pietrzak-Nowacka M, Safranow K, Byra E, Nowosiad M, Marchelek-My\u015bliwiec M, Ciechanowski K (2010) Glucose metabolism parameters during an oral glucose tolerance test in patients with autosomal dominant polycystic kidney disease. Scand J Clin Lab Invest 70:561\u2013567. https:\/\/doi.org\/10.3109\/00365513.2010.527012","journal-title":"Scand J Clin Lab Invest"},{"key":"5406_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, Brosnahan G et al (2018) Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol 29:571\u2013578. https:\/\/doi.org\/10.1681\/ASN.2017070819","journal-title":"J Am Soc Nephrol"},{"key":"5406_CR19","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1038\/s41598-021-84609-8","volume":"11","author":"MM Baliga","year":"2021","unstructured":"Baliga MM, Klawitter J, Christians U, Hopp K et al (2021) Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep 11:6629. https:\/\/doi.org\/10.1038\/s41598-021-84609-8","journal-title":"Sci Rep"},{"key":"5406_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.ajkd.2018.02.362","volume":"72","author":"H-R Yun","year":"2018","unstructured":"Yun H-R, Kim H, Park JT, Chang TI et al (2018) Obesity, metabolic abnormality, and progression of CKD. Am J Kidney Dis 72:400\u2013410. https:\/\/doi.org\/10.1053\/j.ajkd.2018.02.362","journal-title":"Am J Kidney Dis"},{"key":"5406_CR21","doi-asserted-by":"publisher","first-page":"F1087","DOI":"10.1152\/ajprenal.00340.2016","volume":"311","author":"B Spoto","year":"2016","unstructured":"Spoto B, Pisano A, Zoccali C (2016) Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol 311:F1087\u2013F1108. https:\/\/doi.org\/10.1152\/ajprenal.00340.2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"5406_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jpeds.2018.06.007","volume":"202","author":"S Lalan","year":"2018","unstructured":"Lalan S, Jiang S, Ng DK, Kupferman F et al (2018) Cardiometabolic risk factors, metabolic syndrome, and chronic kidney disease progression in children. J Pediatr 202:163\u2013170. https:\/\/doi.org\/10.1016\/j.jpeds.2018.06.007","journal-title":"J Pediatr"},{"key":"5406_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.ajkd.2008.03.003","volume":"52","author":"MC Foster","year":"2008","unstructured":"Foster MC, Hwang S-J, Larson MG, Lichtman JH et al (2008) Overweight, obesity, and the development of stage 3 CKD: the Framingham heart study. Am J kidney Dis 52:39\u201348. https:\/\/doi.org\/10.1053\/j.ajkd.2008.03.003","journal-title":"Am J kidney Dis"},{"key":"5406_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000500436","volume":"12","author":"A Spinelli","year":"2019","unstructured":"Spinelli A, Buoncristiano M, Kovacs VA, Yngve A et al (2019) Prevalence of severe obesity among primary school children in 21 European countries. Obes Facts 12:244\u2013258. https:\/\/doi.org\/10.1159\/000500436","journal-title":"Obes Facts"},{"key":"5406_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1067\/mpd.2002.125228","volume":"140","author":"JM Sorof","year":"2002","unstructured":"Sorof JM, Poffenbarger T, Franco K, Bernard L et al (2002) Isolated systolic hypertension, obesity, and hyperkinetic hemodynamic states in children. J Pediatr 140:660\u2013666. https:\/\/doi.org\/10.1067\/mpd.2002.125228","journal-title":"J Pediatr"},{"key":"5406_CR26","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1056\/NEJMoa012578","volume":"346","author":"R Sinha","year":"2002","unstructured":"Sinha R, Fisch G, Teague B, Tamborlane WV et al (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802\u2013810. https:\/\/doi.org\/10.1056\/NEJMoa012578","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"5406_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1399-5448.2007.00329.x","volume":"8","author":"J Shaw","year":"2007","unstructured":"Shaw J (2007) Epidemiology of childhood type 2 diabetes and obesity. Pediatr Diabetes 8(Suppl 9):7\u201315. https:\/\/doi.org\/10.1111\/j.1399-5448.2007.00329.x","journal-title":"Pediatr Diabetes"},{"key":"5406_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMoa1502821","volume":"373","author":"AC Skinner","year":"2015","unstructured":"Skinner AC, Perrin EM, Moss LA, Skelton JA (2015) Cardiometabolic risks and severity of obesity in children and young adults. N Engl J Med 373:1307\u20131317. https:\/\/doi.org\/10.1056\/NEJMoa1502821","journal-title":"N Engl J Med"},{"key":"5406_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1056\/NEJMoa072515","volume":"357","author":"JL Baker","year":"2007","unstructured":"Baker JL, Olsen LW, S\u00f8rensen TIA (2007) Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 357:2329\u20132337. https:\/\/doi.org\/10.1056\/NEJMoa072515","journal-title":"N Engl J Med"},{"key":"5406_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1001\/archinte.162.16.1867","volume":"162","author":"PWF Wilson","year":"2002","unstructured":"Wilson PWF, D\u2019Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867\u20131872. https:\/\/doi.org\/10.1001\/archinte.162.16.1867","journal-title":"Arch Intern Med"},{"key":"5406_CR31","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00125-015-3602-z","volume":"58","author":"CS Yajnik","year":"2015","unstructured":"Yajnik CS, Katre PA, Joshi SM, Kumaran K et al (2015) Higher glucose, insulin and insulin resistance (HOMA-IR) in childhood predict adverse cardiovascular risk in early adulthood: the Pune children\u2019s study. Diabetologia 58:1626\u20131636. https:\/\/doi.org\/10.1007\/s00125-015-3602-z","journal-title":"Diabetologia"},{"key":"5406_CR32","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Steele C, Gitomer B, Wang W et al (2021) Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol 16:908\u2013915. https:\/\/doi.org\/10.2215\/CJN.16871020","journal-title":"Clin J Am Soc Nephrol"},{"key":"5406_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ki.1997.360","volume":"52","author":"K Vareesangthip","year":"1997","unstructured":"Vareesangthip K, Tong P, Wilkinson R, Thomas TH (1997) Insulin resistance in adult polycystic kidney disease. Kidney Int 52:503\u2013508. https:\/\/doi.org\/10.1038\/ki.1997.360","journal-title":"Kidney Int"},{"key":"5406_CR34","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1046\/j.1523-1755.1998.00898.x","volume":"53","author":"D Fliser","year":"1998","unstructured":"Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A et al (1998) Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53:1343\u20131347. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00898.x","journal-title":"Kidney Int"},{"key":"5406_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/0971-4065.107195","volume":"23","author":"K Turkmen","year":"2013","unstructured":"Turkmen K, Tufan F, Sel\u00e7uk E, Akp\u0131nar T, Oflaz H, Ecder T (2013) Neutrophil-to-lymphocyte ratio, insulin resistance, and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Indian J Nephrol 23:34\u201340. https:\/\/doi.org\/10.4103\/0971-4065.107195","journal-title":"Indian J Nephrol"},{"key":"5406_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2215\/CJN.04140510","volume":"6","author":"V Menon","year":"2011","unstructured":"Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2011) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6:7\u201313. https:\/\/doi.org\/10.2215\/CJN.04140510","journal-title":"Clin J Am Soc Nephrol"},{"key":"5406_CR37","doi-asserted-by":"publisher","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.e214","volume":"6","author":"RA DeFronzo","year":"1979","unstructured":"DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 6:E214. https:\/\/doi.org\/10.1152\/ajpendo.1979.237.3.e214","journal-title":"Am J Physiol Endocrinol Metab Gastrointest Physiol"},{"key":"5406_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.tp.0000248759.37146.3d","volume":"83","author":"RA Hamer","year":"2007","unstructured":"Hamer RA, Chow CL, Ong ACM, McKane WS (2007) Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 83:36\u201340. https:\/\/doi.org\/10.1097\/01.tp.0000248759.37146.3d","journal-title":"Transplantation"},{"key":"5406_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/TP.0b013e31820f0877","volume":"91","author":"S Caillard","year":"2011","unstructured":"Caillard S, Eprinchard L, Perrin P, Braun L et al (2011) Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 91:757\u2013764. https:\/\/doi.org\/10.1097\/TP.0b013e31820f0877","journal-title":"Transplantation"},{"key":"5406_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1523-1755.2005.67132.x","volume":"67","author":"AM de Mattos","year":"2005","unstructured":"de Mattos AM, Olyaei AJ, Prather JC, Golconda MS et al (2005) Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation. Kidney Int 67:714\u2013720. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.67132.x","journal-title":"Kidney Int"},{"key":"5406_CR41","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1093\/ndt\/gfr744","volume":"27","author":"B Reed","year":"2011","unstructured":"Reed B, Helal I, McFann K, Wang W et al (2011) The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 27:2862\u20132865. https:\/\/doi.org\/10.1093\/ndt\/gfr744","journal-title":"Nephrol Dial Transplant"},{"key":"5406_CR42","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ekir.2019.12.007","volume":"5","author":"IY Kuo","year":"2020","unstructured":"Kuo IY, Chapman AB (2020) Polycystins, ADPKD, and cardiovascular disease. Kidney Int reports 5:396\u2013406. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.007","journal-title":"Kidney Int reports"},{"key":"5406_CR43","doi-asserted-by":"publisher","first-page":"e0192895","DOI":"10.1371\/journal.pone.0192895","volume":"13","author":"RW Major","year":"2018","unstructured":"Major RW, Cheng MRI, Grant RA, Shantikumar S et al (2018) Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLoS ONE 13:e0192895. https:\/\/doi.org\/10.1371\/journal.pone.0192895","journal-title":"PLoS ONE"},{"key":"5406_CR44","doi-asserted-by":"publisher","first-page":"e5595","DOI":"10.1097\/MD.0000000000005595","volume":"95","author":"L Sans","year":"2016","unstructured":"Sans L, Pascual J, Radosevic A, Quintian C et al (2016) Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients. Medicine (Baltimore) 95:e5595. https:\/\/doi.org\/10.1097\/MD.0000000000005595","journal-title":"Medicine (Baltimore)"},{"key":"5406_CR45","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1159\/000486011","volume":"42","author":"S Lai","year":"2017","unstructured":"Lai S, Mastroluca D, Matino S, Panebianco V et al (2017) Early markers of cardiovascular risk in autosomal dominant polycystic kidney disease. Kidney Blood Press Res 42:1290\u20131302. https:\/\/doi.org\/10.1159\/000486011","journal-title":"Kidney Blood Press Res"},{"key":"5406_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12882-021-02313-1","volume":"22","author":"JL Gorriz","year":"2021","unstructured":"Gorriz JL, Arroyo D, D\u2019Marco L, Torra R et al (2021) Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease. BMC Nephrol 22:110. https:\/\/doi.org\/10.1186\/s12882-021-02313-1","journal-title":"BMC Nephrol"},{"key":"5406_CR47","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.xkme.2021.03.004","volume":"3","author":"KL Nowak","year":"2021","unstructured":"Nowak KL, Murray K, You Z, Gitomer B et al (2021) Pain and obesity in autosomal dominant polycystic kidney disease: a post hoc analysis of the halt progression of polycystic kidney disease (HALT-PKD) studies. Kidney Med 3:536-545.e1. https:\/\/doi.org\/10.1016\/j.xkme.2021.03.004","journal-title":"Kidney Med"},{"key":"5406_CR48","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1046\/j.1523-1755.2001.00985.x","volume":"60","author":"ZH Bajwa","year":"2001","unstructured":"Bajwa ZH, Gupta S, Warfield CA, Steinman TI (2001) Pain management in polycystic kidney disease. Kidney Int 60:1631\u20131644. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00985.x","journal-title":"Kidney Int"},{"key":"5406_CR49","unstructured":"World Health Organization (2017) Tenfold increase in childhood and adolescent obesity in four decades: new study by Imperial College London and WHO. In: Available online. https:\/\/www.who.int\/news\/item\/11-10-2017-. Accessed 3 Jun 2021"},{"key":"5406_CR50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJMoa0904130","volume":"362","author":"PW Franks","year":"2010","unstructured":"Franks PW, Hanson RL, Knowler WC, Sievers ML et al (2010) Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 362:485\u2013493. https:\/\/doi.org\/10.1056\/NEJMoa0904130","journal-title":"N Engl J Med"},{"key":"5406_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000479801","volume":"8","author":"A Whaley-Connell","year":"2017","unstructured":"Whaley-Connell A, Sowers JR (2017) Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med 8:41\u201349. https:\/\/doi.org\/10.1159\/000479801","journal-title":"Cardiorenal Med"},{"key":"5406_CR52","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.2215\/CJN.01010211","volume":"6","author":"I Helal","year":"2011","unstructured":"Helal I, Reed B, Mcfann K, Yan XD et al (2011) Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2439\u20132443. https:\/\/doi.org\/10.2215\/CJN.01010211","journal-title":"Clin J Am Soc Nephrol"},{"key":"5406_CR53","doi-asserted-by":"publisher","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","volume":"278","author":"A Chagnac","year":"2000","unstructured":"Chagnac A, Weinstein T, Korzets A, Ramadan E et al (2000) Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278:F817-822. https:\/\/doi.org\/10.1152\/ajprenal.2000.278.5.F817","journal-title":"Am J Physiol Renal Physiol"},{"key":"5406_CR54","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/ijms21061994","volume":"21","author":"AS Kahveci","year":"2020","unstructured":"Kahveci AS, Barnatan TT, Kahveci A, Adrian AE et al (2020) Oxidative stress and mitochondrial abnormalities contribute to decreased endothelial nitric oxide synthase expression and renal disease progression in early experimental polycystic kidney disease. Int J Mol Sci 21:1994. https:\/\/doi.org\/10.3390\/ijms21061994","journal-title":"Int J Mol Sci"},{"key":"5406_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fped.2021.596142","volume":"9","author":"MO Murphy","year":"2021","unstructured":"Murphy MO, Huang H, Bauer JA, Schadler A et al (2021) Impact of pediatric obesity on diurnal blood pressure assessment and cardiovascular risk markers. Front Pediatr 9:123. https:\/\/doi.org\/10.3389\/fped.2021.596142","journal-title":"Front Pediatr"},{"key":"5406_CR56","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00467-020-04579-3","volume":"36","author":"M Litwin","year":"2021","unstructured":"Litwin M, Ku\u0142aga Z (2021) Obesity, metabolic syndrome, and primary hypertension. Pediatr Nephrol 36:825\u2013837. https:\/\/doi.org\/10.1007\/s00467-020-04579-3","journal-title":"Pediatr Nephrol"},{"key":"5406_CR57","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1136\/archdischild-2015-310221","volume":"101","author":"M Marlais","year":"2016","unstructured":"Marlais M, Cuthell O, Langan D, Dudley J et al (2016) Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. Arch Dis Child 101:1142\u20131147. https:\/\/doi.org\/10.1136\/archdischild-2015-310221","journal-title":"Arch Dis Child"},{"key":"5406_CR58","doi-asserted-by":"publisher","first-page":"874","DOI":"10.2215\/CJN.11401017","volume":"13","author":"L Massella","year":"2018","unstructured":"Massella L, Mekahli D, Paripovi\u0107 D, Prikhodina L et al (2018) Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:874\u2013883. https:\/\/doi.org\/10.2215\/CJN.11401017","journal-title":"Clin J Am Soc Nephrol"},{"key":"5406_CR59","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1046\/j.1523-1755.2001.0590051654.x","volume":"59","author":"GM Fick-Brosnahan","year":"2001","unstructured":"Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA (2001) Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59:1654\u20131662. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.0590051654.x","journal-title":"Kidney Int"},{"key":"5406_CR60","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/ki.2008.397","volume":"74","author":"MA Cadnapaphornchai","year":"2008","unstructured":"Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192\u20131196. https:\/\/doi.org\/10.1038\/ki.2008.397","journal-title":"Kidney Int"},{"key":"5406_CR61","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/ijo.2016.92","volume":"40","author":"A Mastrangelo","year":"2016","unstructured":"Mastrangelo A, Martos-Moreno G\u00c1, Garc\u00eda A, Barrios V et al (2016) Insulin resistance in prepubertal obese children correlates with sex-dependent early onset metabolomic alterations. Int J Obes (Lond) 40:1494\u20131502. https:\/\/doi.org\/10.1038\/ijo.2016.92","journal-title":"Int J Obes (Lond)"},{"key":"5406_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biom10020291","volume":"10","author":"IK Kwaifa","year":"2020","unstructured":"Kwaifa IK, Bahari H, Yong YK, Noor SM (2020) Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules 10:291. https:\/\/doi.org\/10.3390\/biom10020291","journal-title":"Biomolecules"},{"key":"5406_CR63","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli M, Rowe I, Mannella V, Quilici G et al (2016) 2-Deoxy-D-glucose ameliorates PKD progression. J Am Soc Nephrol 27:1958\u20131969. https:\/\/doi.org\/10.1681\/ASN.2015030231","journal-title":"J Am Soc Nephrol"},{"key":"5406_CR64","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","volume":"11","author":"M Riwanto","year":"2016","unstructured":"Riwanto M, Kapoor S, Rodriguez D, Edenhofer I et al (2016) Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS ONE 11:e0146654. https:\/\/doi.org\/10.1371\/journal.pone.0146654","journal-title":"PLoS ONE"},{"key":"5406_CR65","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1681\/ASN.2015111224","volume":"28","author":"F Grahammer","year":"2017","unstructured":"Grahammer F, Ramakrishnan SK, Rinschen MM, Larionov AA et al (2017) mTOR regulates endocytosis and nutrient transport in proximal tubular cells. J Am Soc Nephrol 28:230\u2013241. https:\/\/doi.org\/10.1681\/ASN.2015111224","journal-title":"J Am Soc Nephrol"},{"key":"5406_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mce.2010.07.022","volume":"330","author":"H Zhang","year":"2010","unstructured":"Zhang H, Kong W-J, Shan Y-Q, Song D-Q et al (2010) Protein kinase D activation stimulates the transcription of the insulin receptor gene. Mol Cell Endocrinol 330:25\u201332. https:\/\/doi.org\/10.1016\/j.mce.2010.07.022","journal-title":"Mol Cell Endocrinol"},{"key":"5406_CR67","doi-asserted-by":"publisher","first-page":"e14250","DOI":"10.14814\/phy2.14250","volume":"7","author":"S Khan","year":"2019","unstructured":"Khan S, Ferdaoussi M, Bautista A, Bergeron V et al (2019) A role for PKD1 in insulin secretion downstream of P2Y1 receptor activation in mouse and human islets. Physiol Rep 7:e14250. https:\/\/doi.org\/10.14814\/phy2.14250","journal-title":"Physiol Rep"},{"key":"5406_CR68","doi-asserted-by":"publisher","first-page":"e135700","DOI":"10.1172\/jci.insight.135700","volume":"5","author":"S Kashyap","year":"2020","unstructured":"Kashyap S, Hein KZ, Chini CC, Lika J et al (2020) Metalloproteinase PAPP - a regulation of IGF-1 contributes to polycystic kidney disease pathogenesis. JCI Insight 5:e135700. https:\/\/doi.org\/10.1172\/jci.insight.135700","journal-title":"JCI Insight"},{"key":"5406_CR69","doi-asserted-by":"publisher","first-page":"109698","DOI":"10.1016\/j.cellsig.2020.109698","volume":"73","author":"S Kashyap","year":"2020","unstructured":"Kashyap S, Zeidler JD, Chini CCS, Chini EN (2020) Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease. Cell Signal 73:109698. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109698","journal-title":"Cell Signal"},{"key":"5406_CR70","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2021.03.024","volume":"33","author":"H Ramalingam","year":"2021","unstructured":"Ramalingam H, Kashyap S, Cobo-Stark P, Flaten A et al (2021) A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease. Cell Metab 33:1234-1247.e7. https:\/\/doi.org\/10.1016\/j.cmet.2021.03.024","journal-title":"Cell Metab"},{"key":"5406_CR71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393\u2013403. https:\/\/doi.org\/10.1056\/NEJMoa012512","journal-title":"N Engl J Med"},{"key":"5406_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-0032-1327734","volume":"121","author":"C Seifarth","year":"2013","unstructured":"Seifarth C, Schehler B, Schneider HJ (2013) Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 121:27\u201331. https:\/\/doi.org\/10.1055\/s-0032-1327734","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"5406_CR73","doi-asserted-by":"publisher","first-page":"e2020086","DOI":"10.23750\/abm.v91i3.10127","volume":"91","author":"A Soliman","year":"2020","unstructured":"Soliman A, DeSanctis V, Alaaraj N, Hamed N (2020) The clinical application of metformin in children and adolescents: a short update. Acta Biomed 91:e2020086. https:\/\/doi.org\/10.23750\/abm.v91i3.10127","journal-title":"Acta Biomed"},{"key":"5406_CR74","doi-asserted-by":"publisher","unstructured":"Masarwa R, Brunetti VC, Aloe S, Henderson M, Platt RW, Filion KB (2021) Efficacy and safety of metformin for obesity: a systematic review. Pediatrics 147:e20201610.\u00a0https:\/\/doi.org\/10.1542\/peds.2020-1610","DOI":"10.1542\/peds.2020-1610"},{"key":"5406_CR75","doi-asserted-by":"publisher","first-page":"e0226303","DOI":"10.1371\/journal.pone.0226303","volume":"14","author":"J Bassols","year":"2019","unstructured":"Bassols J, Mart\u00ednez-Calcerrada J-M, Osiniri I, D\u00edaz-Rold\u00e1n F et al (2019) Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: a pilot study. PLoS ONE 14:e0226303. https:\/\/doi.org\/10.1371\/journal.pone.0226303","journal-title":"PLoS ONE"},{"key":"5406_CR76","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","volume":"138","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Sch\u00e4fer M, Truong U, Cree-Green M et al (2018) Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus. Circulation 138:2895\u20132907. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035525","journal-title":"Circulation"},{"key":"5406_CR77","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2337\/dc09-0258","volume":"32","author":"MH Park","year":"2009","unstructured":"Park MH, Kinra S, Ward KJ, White B, Viner RM (2009) Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32:1743\u20131745. https:\/\/doi.org\/10.2337\/dc09-0258","journal-title":"Diabetes Care"},{"key":"5406_CR78","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1210\/jc.2012-2710","volume":"98","author":"D Kendall","year":"2013","unstructured":"Kendall D, Vail A, Amin R, Barrett T et al (2013) Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 98:322\u2013329. https:\/\/doi.org\/10.1210\/jc.2012-2710","journal-title":"J Clin Endocrinol Metab"},{"key":"5406_CR79","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.kint.2020.04.059","volume":"98","author":"ME De Broe","year":"2020","unstructured":"De Broe ME, Jouret F (2020) Does metformin do more benefit or harm in chronic kidney disease patients? Kidney Int 98:1098\u20131101. https:\/\/doi.org\/10.1016\/j.kint.2020.04.059","journal-title":"Kidney Int"},{"key":"5406_CR80","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"MJ Crowley","year":"2017","unstructured":"Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB et al (2017) Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166:191\u2013200. https:\/\/doi.org\/10.7326\/M16-1901","journal-title":"Ann Intern Med"},{"key":"5406_CR81","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.kint.2021.07.021","volume":"100","author":"ACM Ong","year":"2021","unstructured":"Ong ACM, Gansevoort RT (2021) TAMEing ADPKD with metformin: safe and effective? Kidney Int 100:513\u2013515. https:\/\/doi.org\/10.1016\/j.kint.2021.07.021","journal-title":"Kidney Int"},{"key":"5406_CR82","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94:26\u201339. https:\/\/doi.org\/10.1016\/j.kint.2017.12.027","journal-title":"Kidney Int"},{"key":"5406_CR83","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"5406_CR84","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2215\/CJN.14901219","volume":"15","author":"A Levin","year":"2020","unstructured":"Levin A, Perkovic V, Wheeler DC, Hantel S et al (2020) Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial. Clin J Am Soc Nephrol 15:1433\u20131444. https:\/\/doi.org\/10.2215\/CJN.14901219","journal-title":"Clin J Am Soc Nephrol"}],"updated-by":[{"DOI":"10.1007\/s00467-022-05624-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000}}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05406-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05406-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T15:05:38Z","timestamp":1658502338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05406-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5406"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05406-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00467-022-05624-z","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00467-022-05624-z","URL":"https:\/\/doi.org\/10.1007\/s00467-022-05624-z","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}